Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge, with its stock price soaring 38.56%.
The dramatic move follows reports that Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on the Hims & Hers telehealth platform. This new partnership brings an end to a dispute between the two companies that had escalated into a legal battle last month, removing a significant overhang and opening a substantial new revenue channel for the telehealth provider.